Clinical Trial

the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 18, 2026 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
MTAP deletion frequently occurs in osteosarcoma, and PRMT5 has been identified as a synthetic lethal target for cancers with homozygous deletion of the MTAP gene, making it a promising target for anti-tumor drug development.This study aims to evaluate the overall status of MTAP deficiency in the tissues of osteosarcoma patients and its correlation with clinical features such as metastasis and immune subtypes by examining the MTAP protein expression levels in previous histological samples of the patients and combining this with their clinicopathological data.
Trial Details
NCT Number NCT07593573
Lead Sponsor Peking University People's Hospital
Collaborators: Sailan(Hangzhou)Biopharmaceutical Technology Co.,Ltd.
Conditions Osteosarcoma, MTAP Deletion, Immunohistochemistry
Enrollment 100 participants
Start Date 2025-12-15
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-12-14 (estimated)
Updated on ClinicalTrials.gov 2026-05-18